The role of intestinal disbiosis in the development of mitochondrial dysfunction and nonalcoholic fatty liver disease
https://doi.org/10.21518/2079-701X-2018-6-85-95
Abstract
Taking into account the numerous metabolic functions of microflora, violation of its colonization resistance is considered as a trigger factor in the development of a number of different diseases. Thus, studies conducted in recent years demonstrate a significant relationship of dysbiotic intestinal microflora disorders with the pathogenesis of NAFLD, caused by damage to the mitochondria. It is proved that mitochondrial dysfunction plays a significant role not only in the development of SEX, which leads to membrane damage, necrosis and apoptosis of hepatocytes, but also to the progression of steatosis. Clinical signs of acute and chronic liver disease suggests that, regardless of their etiology, clinical manifestations, come to the fore phenomena are typical for mitochondrial dysfunction. The data presented in the article demonstrate the importance of dysbiotic changes in the development of mitochondrial dysfunction, the formation of steatosis in non-alcoholic fatty liver disease, with its subsequent transformation into steatohepatitis and progression to fibrosis and cirrhosis.
About the Authors
P. V. Seliverstov
Mechnikov North-Western State Medical University, Saint-Petersburg, Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
S. I. Sitkin
Mechnikov North-Western State Medical University, Saint-Petersburg, Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
V, G. Radchenko
Mechnikov North-Western State Medical University, Saint-Petersburg, Russia
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
References
1. Radchenko VG. et al. The treatment algorithm for non-alcoholic fatty liver disease and the role of mitochondrial dysfunction in the development of NAFLD. Pharmatek, 2017, 6: 14-21.
2. Bondarenko VM. The role of opportunistic pathogenic bacteria in chronic inflammatory processes of various localizations. Tver: Triada, 2011. 88 p.
3. Bondarenko VM, Matsulevich ТV. Intestine dysbacteriosis as a clinical and laboratory syndrome: status update on the problem: a guide for practitioners. Moscow: GEOTAR-Media, 2007. 304 p.
4. Bondarenko VM. Dysbacteriosis. M.: Meditsina, 1994, p. 334.
5. Vorobiev AA, Lykova EA. Normal microflora bacteria: biological properties and protective functions. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii, 1999, 6: 102-105.
6. Vorobiev AA, Nesvizhsky YuV, Zudenkov AE, et al. A comparative study of parietal and luminal colon micro-flora in an experiment in mice. Zhurn. Mikrobiol., Epidemiol. i Immunobiol., 2001, 1: 62-7.
7. Gabrielyan NI, Gorskaya EM, Snegova ND. Functions of the gastrointestinal tract microflora and the consequences of its disorders after surgical interventions. Antibiotiki i Khimioterapiya, 2000, 9: 24-29.
8. Grinevich VB, Uspensky YuP, Dobrynin VМ, et al. Clinical aspects of diagnosis and treatment of intestinal dysbiosis in general therapeutic practice. SPb., 2003, p. 36.
9. Sitkin SI, et al. Dysbiosis in ulcerative colitis and celiac disease and its therapeutic correction by butyric acid plus inulin. Eksp Klin Gastroenterol, 2017,(6):77–98.
10. Erofeev NP, Seliverstov PV, Radchenko VG. Clinical physiology of the colon. Mechanisms of action of short-chain fatty acids in normal and pathological conditions. M .: «4TE ART» LLC, 2012. 56 p.
11. Zakirov IG. Intestinal dysbacteriosis in chronic viral hepatitis. Kazan, 2003. 86 p.
12. Ivashkin VT. Liver and bile duct disorders. A guide for practitioners. M-Vesti Publishing House, 2002.
13. Korshunov VM, at al. The qualitative composition of normal intestinal microflora in subjects of various age groups. Zhurnal Mikrobio logii, Epidemiologii i Immunobiologii, 2001, 2: 57-62.
14. Dolgov VV. Clinical laboratory diagnostics. National guidelines. Moscow: GEOTAR-Media, 2012. 928 p.
15. Korvyakova ER. Intestinal disbiosis after bacterial infections and methods of its correction. Synopsis of thesis. MD. SPb, 2000, p. 44.
16. Minushkin ON, Ardatskaya M.D. Dysbacteri osis (dysbiosis) of the intestine: modern presentation, diagnosis and treatment correction. M., 2008. 50 p.
17. Sitkin SI, et al. Gut microbial and endogenous metabolism alterations in ulcerative colitis and celiac disease: A metabolomics approach to identify candidate biomarkers of chronic intestinal inflammation associated with dysbiosis. Eksp Klin Gastroenterol, 2017,(7):4–50.
18. Lazebnik LB, et al. Nonalcoholic fatty liver disease: clinic, diagnostics, treatment (recommendations for therapists, 2nd edition). Eksp Klin Gastroenterol, 2017,(2):22–37.
19. Industry standard OST 91500.11.0004-2003 «Protocol of patients management. Dysbacteriosis of the intestine. « Order of the Ministry of Health of the Russian Federation No. 231 of 09.06.2003.
20. Petrov LN. Bacterial probiotics: biotechnology, clinic, choice algorithm. SPb: Federal State Unitary Enterprise State Research Institute of Especially Pure Bioproducts. 2008, p. 31.
21. Petukhov VA, Sternina LA, Travkin AE. Liver dysfunction and dysbiosis in Saveliev lipid distress syndrome: a modern view of the problem. Consilium Medicum, 2004, 6 (6): 406-9.
22. Radchenko VG, et al. Dietary fiber in clinical practice. Klinicheskie Perspektivy Gastroenterologii, Gepatologii, 2010, 1: 20-27.
23. Chikhacheva EA. Enhancement of therapy efficacy in patients with liver diseases against the background of intestinal dysbiosis associated with altered short-chain fatty acids. Lechashchiy Vrach, 2013, 1: 1-6.
24. Radchenko VG, Shabrov AV, Zinovieva EN, Sitkin SI. Liver and bile duct diseases: a guide for practitioners. SPb.: SpecLit, 2011. 526 p.
25. Radchenko VG, Safronenkova IG, Seliverstov PV. Clinical aspects of diagnosis and treatment of intestinal dysbiosis in patients with chronic liver diseases. St. Petersburg, 2009, 28 p.
26. Radchenko VG, Sitkin SI, Seliverstov PV. Principles of diagnosis and treatment of intestinal dysbiosis in patients with chronic liver diseases. SPb, 2010, 36 p.
27. Teterina LA, et al. The role of the colon microflora in the development of latent hepatic encephalopathy. Lechashchiy Vrach, 2012, 9: 73-78.
28. Radchenko VG, Suvorov AN, Sitkin SI, Seliverstov PV, Teterina LA. Therapeutic potential of synbiotics in patients with chronic liver diseases. St. Petersburg, 2010, 30 p.
29. Seliverstov PV, et al. The role of intestinal microbiocenosis and microbiota exometabo-lites disorders in the development of non-alcoholic fatty liver disease. Gastroenterologiya Sankt-Peterburga, 2016, 3–4: M21-M22.
30. Seliverstov PV, Radchenko VG. The role of mitochondrial cytopathy in steatosis in patients with nonalcoholic fatty liver disease. Effektivnaya Farmakoterapiya, 2017, 16: 16-24
31. Seliverstov PV. Intestinal dysbiosis and its correction methods in patients with chronic liver diseases. Synopsis of thesis. PhD in medicine. St. Petersburg, 2011. 23 p.
32. Seliverstov PV, Sitkin SI, Radchenko VG, Lazebnik LB, Avalueva EB, Vakhitov TYa, Demyanova EV, Skvortsova TE, Prikhodko EM, Suvorova MA. Saccharomyces boulardii modulates the composition of the gut microbiota in patients with non-alcoholic fatty liver disease (NAFLD), thus preventing the progression of the disease. Eksp Klin Gastroenterol, 2018,(2).
33. Tkachenko EI. Nutrition, human endoecology, health, illness. A modern view of the problem of their interrelations. Terapevticheskiy Arkhiv, 2004, 2: 67-71.
34. Tkachenko EI. Theory of adequate nutrition and trophology as a methodological basis for the treatment and prevention of internal organs diseases. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Kolonoproktologii, 2001, 11 (4): 15-22.
35. Tkachenko EI, Suvorov AN. Intestinal dysbiosis: a guide on diagnosis and treatment. St. Petersburg, 2009. 35 p.
36. Firsov NN. Microbiology: a glossary of terms. M.: Drofa, 2006. 256 p.
37. Shenderov BA. Functional nutrition and its role in the prevention of meta bolic syndrome. Moscow: DeLi-print, 2008. 319 p.
38. Bellantani S, Saccoccio G, Masutti F et аl. Prevalence and risk factors for hepatic steatosis in northern Italy. An. Intern. Med., 2000, 132: 112–7.
39. Bosch J, Garcia-Pagan J. Complications of cirrhosis. Portal hypertenstion. Hepatology, 2000, 32: 141–56.
40. Cebra J. Influences of microbiota on intestinal immune system development. Am. J. Clin. Nutr., 1999, 69: 1046–51.
41. Duboc H et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation ininflammatory bowel diseases. Gut, 2013 Apr, 62(4): 531–9.doi: 10.1136/gutjnl-2012–302578.
42. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Sciences, 2004, 305: 626-629.
43. Farnaud S, Evans RW. Lactoferrina multifunctional protein with antimicrobial properties. Mol. Immunol., 2003, 40(7): 395-405.
44. Fukata M, Arditi M. The role of pattern recognition receptors in intestinal inflammation. Mucosal Immunol, 2013 May, 6(3): 451–63. doi: 10.1038/mi.2013.13.
45. Lupetti A, Paulusma-Annema A, Welling MM, Dogterom-Ballering H, Brouwer CP, Senesi S, Van Dissel JT, Nibbering PH. Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Anti microb. Agents Chemother., 2003, 47(1): 262-267.
46. Ibdah JA et al. Lack of mitochondrial trifunctional protein in mice causes neonatal hypoglycemia and sudden death. J. Clin. Invest., 2001, 107: 1403-1409.
47. Mark N, de Alwis W, Day CP. Current and future therapeuticstrategies in NAFLD. Curr. Pharm. Des., 2010, 16(17): 1958-1962.
48. Matsuoka K, Kanai T. The gut microbiota and inflammatorybowel disease. Semin Immunopathol, 2015 Jan, 37(1): 47–55. doi: 10.1007/ s00281–014–0454–4.
49. Medina J, Moreno-Otero R. Pathophysiological basis for antioxidant therapy in chronic liver disease. Drugs, 2005, 65(17): 2445-2461.
50. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potentiallinks with mitochondrial dysfunction. Diabetes, 2006, 55(suppl. 2): S9-S15.
51. Wei Y et al. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J. Gastroenterol., 2008, 14: 193-199.
52. Powel EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology, 2005, 42: 5-13.
53. Vakhitov TY, Chalisova NI, Sitkin SI, Sall TS, Shalaeva ON, Demyanova EV, Morugina AS, Vinogradova AF, Petrov AV, Nozdrachev AD. Low-molecular-weight components of the metabolome control the proliferative activity in cellular and bacterial cultures. Dokl Biol Sci, 2017 Jan, 472(1): 8-10. doi: 10.1134/S0012496617010069.
54. Swidsinski A, Loening-Baucke V, Herber A. Mucosal flora in Crohn’s disease and ulcerative colitis – an overview. J Physiol Pharmacol, 2009 Dec, 60(Suppl 6): 61–71.
55. Sharma M, Shukla G. Metabiotics: One Step ahead of Probiotics; an Insight into Mechanisms Involved in Anticancerous Effect in Colorectal Cancer. Front Microbiol, 2016 Dec 2, 7: 1940. doi: 10.3389/fmicb.2016.01940.
56. Shenderov BA. Metabiotics: novel idea or natural development of probiotic conception. Microb Ecol Health Dis, 2013 Apr 12, 24. doi: 10.3402/ mehd.v24i0.20399.
57. Quigley EM. Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet? Nat Rev Gastroenterol Hepatol, 2017 May, 14(5): 315-320. doi:10.1038/nrgastro.2017.29.
58. Chang CY et al. Therapy of NAFLD: Antioxidants and Cytoprotective Agents. J. Clin. Gastroenterol., 2006, 40: S51-S60.
59. Adams LA et al.The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology, 2005, 129: 113-121.
60. Valko M, Leibfritz D, Moncol J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell. Biol., 2007, 39(1): 44-84.
61. Younossi ZM. Review article: current management of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Aliment. Pharmacol. Ther., 2008, 28(1): 2-12.
Review
For citations:
Seliverstov PV, Sitkin SI, Radchenko VG. The role of intestinal disbiosis in the development of mitochondrial dysfunction and nonalcoholic fatty liver disease. Meditsinskiy sovet = Medical Council. 2018;(6):89-95. (In Russ.) https://doi.org/10.21518/2079-701X-2018-6-85-95
Views:
982
Email this article 